| Roy Michael Lukat, MED | |
|
445 S Highway 27, Ste. 100, Somerset, KY 42501-3445 | |
| (606) 679-3866 | |
| Not Available |
| Full Name | Roy Michael Lukat |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 445 S Highway 27, Somerset, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962697573 | NPI | - | NPPES |
| 500050346 | Medicaid | KY | |
| 70000401 | Medicaid | KY |
| Mailing Address | Practice Location Address |
|---|---|
| Roy Michael Lukat, MED 445 S Highway 27, Ste. 100, Somerset, KY 42501-3445 Ph: (606) 679-3866 | Roy Michael Lukat, MED 445 S Highway 27, Ste. 100, Somerset, KY 42501-3445 Ph: (606) 679-3866 |
News Archive
The WHO has said it will assist government officials evaluating whether the presence of bacteria containing the NDM-1 gene in the water supply in New Delhi poses health risks, Agence France-Presse reports. The announcement comes after the Lancet last week published a report that bacteria carrying NDM-1, a gene that enables resistance to a variety of antibiotics, "was found in 51 out of 171 New Delhi samples taken from water pools and two out of 50 tap water samples," the news service writes.
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.
Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.
Investigators from the Centers for Disease Control and Prevention describe pathologic findings from 40 case reports of fungal infection in patients who had been given contaminated epidural, paraspinal, or intra-articular (into joints) steroid injections and correlate these findings with clinical and laboratory data.
› Verified 6 days ago
Dr. Joseph Currie Luckett I, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 402 Coomer St, Ste. 101, Somerset, KY 42503 Phone: 606-451-0098 | |
Robert Moore Hearing Aid Center, Dba Beltone Audiologist Medicare: Not Enrolled in Medicare Practice Location: 409 Ogden St, Somerset, KY 42501 Phone: 606-679-1965 Fax: 606-678-8465 | |
Bluegrass Hearing Clinic, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 25 Medpark West, Suite 2, Somerset, KY 42503 Phone: 606-492-2009 |